Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an ...

Sexually transmitted infections (STIs) have become increasingly common worldwide and now represent a major public health concern, particularly among young people aged 15 to 24 years. Globally, more ...

Submissions are supported by data from the Phase 3 Viti-Up clinical studies demonstrating upadacitinib achieved the co-primary endpoints of at least a 50% improvement ...

Investigational antiviral pritelivir demonstrates efficacy and improved tolerability over current treatments for refractory HSV in high-risk patients.

HSV will entertain Bayern Munich after successive goalless draws with Borussia Mönchengladbach and St. Pauli. While they ...

Italian pharma Alfasigma has penned a 125 million euro ($145 million) deal for the rights to an injectable form of an investigational herpes simplex virus (HSV) encephalitis treatment. Germany’s ...

BOLOGNA, Italy and MUNICH, Jan. 14, 2026 /PRNewswire/ -- Alfasigma S.p.A. ("Alfasigma"), a global pharmaceutical company, and Innovative Molecules GmbH ("Innovative Molecules"), a clinical-stage ...

The trial enrolled and treated 101 immunocompromised patients with refractory or resistant HSV infection.

We go to school, study further, then learn new things in our chosen careers. But no matter how much knowledge we acquire, ...